Surrozen Filed FDA Application for Diabetes Drug
The company submitted an Investigational New Drug application for a new therapy to treat diabetic macular edema.
Updated on Sept. 24, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to deliver on their clinical trial promises?
Surrozen has submitted an Investigational New Drug application to the FDA for SZN-8141, a treatment for diabetic macular edema. The company saw its share price surge 98.45% following the announcement.
Why it matters
The therapy aims to improve retinal vascular health and address vascular leakage by combining Wnt pathway activation with VEGF inhibition. This approach seeks to provide a novel therapeutic option for patients suffering from diabetes-related eye complications.
SZN-8141 is designed to reduce neovascularization through Wnt pathway activation and VEGF inhibition. Preclinical rodent studies supported the development of this candidate before its transition to the FDA application process.
The players
Surrozen
Surrozen is a biotechnology company focused on discovering and developing tissue-regenerative therapies.
FDA
The Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices in the United States.
The details
Surrozen plans to evaluate the drug candidate in a Phase 1b/2a clinical trial titled DUET. This study will be the first step in assessing the efficacy of the treatment in humans following successful results in preclinical rodent models.
Timeline
June 30, 2026: The company reported $102.0 million in cash and cash equivalents.
September 24, 2026: Surrozen submitted the IND application and shares increased to $32.07.
Late 2026: Patient enrollment for the clinical trial is expected to begin.
Second half of 2027: Initial clinical results are anticipated.
Deeper Dive
The development of SZN-8141 for the DUET clinical trial represents a move toward testing regenerative therapies in human populations. This trial will determine whether the benefits observed in preclinical models translate to effective outcomes in patients with diabetic eye disease.
This development represents a potential future treatment option for those currently managing diabetic macular edema. Patients may eventually benefit from new therapeutic approaches targeting retinal health, though the drug is not yet available for clinical use.
The takeaway
The move into clinical trials highlights the company effort to address complex complications associated with long-term diabetes. Future progress depends on the safety and efficacy data generated during the upcoming human trials.
What happens next
Surrozen plans to commence patient enrollment for its DUET clinical trial by late 2026, followed by the release of initial clinical results anticipated in the second half of 2027.
Further reading
For more information on current treatment trends, visit the Diabetes section.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust pharmaceutical companies to deliver on their clinical trial promises?
